Abstract Number: 519 • 2012 ACR/ARHP Annual Meeting
Sex-Specific Regulatory T Cell Dysfunction in a Mouse Model of Sjögren Syndrome
Background/Purpose: CD4+Foxp3+ regulatory T cells (Tregs) are a specialized population of lymphocytes which prevent autoimmunity in normal hosts. Treg dysfunction has been implicated in autoimmunity; however results…Abstract Number: 520 • 2012 ACR/ARHP Annual Meeting
Genetic Associations to Germinal Centre Formation in Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease mainly affecting the salivary and lacrimal glands causing xerostomia and keratoconjunctivitis sicca. Focal mononuclear cell…Abstract Number: 521 • 2012 ACR/ARHP Annual Meeting
Differences in Genome-Wide DNA Methylation Profiles Across Multiple Cell and Tissue Types in Sjögren’s Syndrome (SS)
Background/Purpose: Increasing evidence supports a role for epigenetic factors, including DNA methylation status, in autoimmune disease risk and severity. Our goal is to characterize DNA…Abstract Number: 522 • 2012 ACR/ARHP Annual Meeting
Genetic Variation in the NCR3 Locus Is Associated with Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in Scandinavian Samples
Background/Purpose: Candidate gene studies in primary Sjögren’s syndrome (pSS) have identified polymorphisms in genes involved in the type I interferon (IFN) system and the type…Abstract Number: 523 • 2012 ACR/ARHP Annual Meeting
Use of Global Gene Expression Profiling to Characterize Sjögren’s Patients Who Underexpress Interferon-Inducible Genes
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth. We previously reported overexpression of interferon-inducible (IFI) genes…Abstract Number: 524 • 2012 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts in Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…Abstract Number: 525 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
Background/Purpose: Sjögren’s syndrome (SS), characterized by lymphocytic infiltration of exocrine glands, is a progressive autoimmune exocrinopathy present in 0.7-1% of Europeans. To better understand the…Abstract Number: 526 • 2012 ACR/ARHP Annual Meeting
Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Background/Purpose: Salivary glands are a prominent target organ in Sjögren’s syndrome (SS), with patients having abnormal secretory function and inflammatory infiltration of these glands. Little…Abstract Number: 527 • 2012 ACR/ARHP Annual Meeting
Multiplexed Nanostring Screening for Salivary Gland Viral Elements in Sjogren’s Syndrome
Background/Purpose: To test the hypothesis that viruses are associated with Sjogren’s syndrome, salivary gland RNA extracts from Sjogren’s patients and non-Sjogren’s controls were screened for…Abstract Number: 528 • 2012 ACR/ARHP Annual Meeting
Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Background/Purpose: To establish an easy and practical assay for detection of systemic Interferon (IFN) type I activation in primary Sjögren's syndrome (pSS). The monocyte IFN…Abstract Number: 529 • 2012 ACR/ARHP Annual Meeting
The Axis P2X7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren’s Syndrome?
Background/Purpose: The exact cause of exocrine gland dysfunction in primary Sjögren’s syndrome (pSS) has not been fully delineated, but it is thought that both innate…Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…Abstract Number: 491 • 2012 ACR/ARHP Annual Meeting
Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Background/Purpose: Published data have shown that approximately one-third of patients with RA are treated with biologic (Bio) monotherapy (MT) (without concomitant DMARD) and a considerable…Abstract Number: 492 • 2012 ACR/ARHP Annual Meeting
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Background/Purpose: There are currently five anti-TNF agents that have been approved for various autoimmune illnesses. There is no convincing evidence that any one of these…Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…
ACR Meeting Abstracts